Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma
- PMID: 28905368
- DOI: 10.1111/bjh.14906
Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma
Keywords: FDG-PET; Hodgkin lymphoma; response assessment.
Comment in
-
Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.Br J Haematol. 2018 Oct;183(1):131-133. doi: 10.1111/bjh.14905. Epub 2017 Aug 18. Br J Haematol. 2018. PMID: 28832981 No abstract available.
Comment on
-
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.Br J Haematol. 2017 Sep;178(5):709-718. doi: 10.1111/bjh.14734. Epub 2017 Jun 7. Br J Haematol. 2017. PMID: 28589704 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
